Bela S. Denes

Bela S. Denes

General Surgery
14050 Fairview Dr
Burnsville, MN 55337

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.

Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.

Journal: The Prostate
Published: January 17, 2025

Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.

Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.

Journal: Clinical genitourinary cancer
Published: June 10, 2024

A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.

A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.

Journal: Urology
Published: September 17, 2018

Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Interesting, but Far from Definitive.

Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Interesting, but Far from Definitive.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 25, 2018

Author Reply.

Author Reply.

Journal: Urology
Published: July 18, 2017

Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.

Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.

Journal: Reviews in urology
Published: November 12, 2016

Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.

Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.

Journal: Urology
Published: October 29, 2016

Mesothelial Inclusions in Pelvic Lymph Nodes Initially Diagnosed as Metastatic Prostate Cancer; the Utility of Second Opinions and Genomic Testing in the Setting of Unexpected Results.

Mesothelial Inclusions in Pelvic Lymph Nodes Initially Diagnosed as Metastatic Prostate Cancer; the Utility of Second Opinions and Genomic Testing in the Setting of Unexpected Results.

Journal: Urology case reports
Published: August 22, 2016

Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis.

Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis.

Journal: Urology practice
Published: November 01, 2015

The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance.

The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance.

Journal: Urology practice
Published: July 01, 2015

A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer.

A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 23, 2014

Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.

Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.

Journal: The journal of sexual medicine
Published: August 19, 2014
Showing 1-12 of 13

Last Updated: 09/26/2026